U.K. drugmaker GW Pharmaceuticals believes its cannabis-derived epilepsy treatment is on its way to Phase III success and FDA approval, moving its CEO to the U.S. as it builds a North American presence.

…read more

Source: GW Pharma CEO jumps to the U.S., betting on epilepsy approval


0 No comments